CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

NCT06973096 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: CART-EGFR-IL13Ra2 cells
BIOLOGICAL: Rituximab or Rituximab biosimilar
DRUG: Fludarabine + Cyclophosphamide combination

Sponsor

University of Pennsylvania

Collaborators

[object Object]